How to Read the WHO CBD Report | Differences Between Medical Formulations, Commercial CBD Products, and Japanese Regulations

Tobacco Column

2022.11.032026.10.20

Safety & Regulatory Information Summary (Verified 2026-10-20):We have retracted the misleading phrasing in an earlier draft suggesting that "because CBD has the WHO's seal of approval, all commercial CBD products are safe." An international organization's report on a pure substance must be strictly distinguished from the safety and legality of commercial products (e-liquids, oils, gummies, etc.) sold in Japan.

Table of Contents for this article.

What the WHO Cannabidiol (CBD) Review Report Covered
Common Misconception: "Recognized by the WHO" Does Not Mean Commercial CBD Vapes or Gummies Are Safe
Beware of Advertising Claims Saying "The WHO Approved Its Safety"
CBD, THC, and CBN Are Different Substances: Check the 2026 Regulations
Why "Safe Because It Is CBD" or "Side-Effect-Free Because It Is Natural" Cannot Be Assumed

What the WHO Cannabidiol (CBD) Review Report Covered

The reports on cannabidiol (CBD) published in 2017–2018 by the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) primarilypure CBD as a substance itself—summarizing findings on its abuse and dependence potential, as well as medical pharmaceuticals (formulations prescribed under a physician's supervision) for specific intractable epilepsies. Source:WHO: Cannabidiol (CBD) Critical Review ReportThe following is a list of the most common problems with the

Common Misconception: "Recognized by the WHO" Does Not Mean Commercial CBD Vapes or Gummies Are Safe

What to check	Scope Covered by the WHO Report	Precautions for Commercial CBD Products (VAPE, Oils, Gummies, etc.)
Target Substance	Pure cannabidiol (CBD) and medical pharmaceutical formulations	Mixed products containing flavorings, solvents, and other cannabinoids, with quality varying by product
Impurities & Adulteration with Other Ingredients	Premised on pharmaceutical-grade quality control	Commercial products must be individually checked for risks of exceeding Δ9-THC limits or contamination with Designated Substances (such as CBN)
Presence of Side Effects	Clinical trials reported drowsiness, diarrhea, elevated liver enzymes, drug interactions, etc.	Not "zero side effects." The FDA also warns of liver injury and drug interaction risks
Japanese Legal Regulations	Recommendations on scheduling under international drug conventions	In Japan, the 2024-12 Δ9-THC residual limits and the 2026-6 designation of CBN as a controlled substance are strictly enforced

Beware of Advertising Claims Saying "The WHO Approved Its Safety"

Some online shops and social media posts advertise that "because the WHO guarantees its safety, you can vape as much as you want" or "any CBD product is legal," which is inaccurate. Whether an actual commercial product complies with Japan's Narcotics and Psychotropics Control Act and Pharmaceuticals and Medical Devices Act must be verified against each product's lot-specific Certificate of Analysis (COA) and Japan's latest regulations.

CBD, THC, and CBN Are Different Substances: Check the 2026 Regulations

CBD (cannabidiol), CBN (cannabinol), and Δ9-THC are distinct compounds treated differently under Japanese law. Product names or package labels such as "CBD Product" or "Hemp-Derived" alone cannot determine all contained ingredients or legal compliance.

CBN became a designated substance on 2026-6-1.The Ministry of Health, Labour and Welfare prohibits in principle the manufacture, import, sale, possession, and use of CBN-containing products. While procedural exceptions exist for medical and research uses, they do not permit general consumer purchase or use. Do not rely on older reviews or past articles claiming "legal" or "recommended." Source:Ministry of Health, Labour and Welfare: Designation of CBN and ProceduresThe following is a list of the most common problems with the

In addition, category-specific residual limits for Δ9-THC took effect on 2024-12-12, and any product exceeding the threshold is classified as a narcotic. These figures are product concentration standards, not intake guidelines.

Product Category	Residual Limit for Δ9-THC
Oils and fats (liquid at room temperature) and powders	10ppm
Aqueous solutions	0.10ppm
All other products (confectionery, solids, VAPE liquids, etc.)	1ppm

Product appearance or naming alone does not determine whether an item falls under the oils/fats category. You must verify the actual product category against a lot-specific Certificate of Analysis (COA). Source:Ministry of Health, Labour and Welfare: Legal Amendments and Residual LimitsThe following is a list of the most common problems with the

Why "Safe Because It Is CBD" or "Side-Effect-Free Because It Is Natural" Cannot Be Assumed

The U.S. FDA highlights risks associated with CBD including liver injury, interactions with concurrent medications, pronounced drowsiness, diarrhea, and appetite changes, while noting scientific unknowns regarding long-term use and differences across intake routes (inhalation, oral, topical). Source:FDA: Risks and Unknowns of CBD ProductsThe following is a list of the most common problems with the

Research on specific prescription CBD formulations cannot be treated as proof that commercial CBD oils, gummies, or VAPE liquids improve insomnia, relieve stress, boost immunity, or aid smoking cessation. Discontinue use immediately and consult a medical professional if you feel unwell. Anyone with preexisting conditions or taking medication should consult a physician or pharmacist rather than self-medicating.